Full-Time

Director – Global Patient Safety Science

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$204k - $255k/yr

Senior, Expert

San Carlos, CA, USA

This position is hybrid, requiring some in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • 8 or more years of drug development experience in the pharmaceutical or related industry, of which at least 4 years include prior Safety Science experience, which includes performance of medical review, safety surveillance/signal detection, and other related risk management activities.
  • A relevant postgraduate qualification (e.g., MD, PharmD, PhD/MSc in a Life sciences discipline, or other post-graduate health professional qualifications).
  • Excellent ability to evaluate, interpret and present scientific data with clarity.
  • Proven success in creating and sustaining strong relationships with internal and external business partners across an organization to create positive partnerships.
  • Experience with interacting with Regulatory Authorities (i.e. FDA, EMA) at type C, B, pre-BLA/MAA meetings, Advisory Committee meetings, or other scientific advice forums.
  • Strong analytical and strategic thinking, problem-solving, and decision-making skills.
  • Excellent communication, collaboration, and team management abilities.
  • Extensive understanding of pharmacovigilance and risk management.
  • Strong clinical leadership and experience.
  • Outstanding emotional intelligence.
Responsibilities
  • Responsible for safety surveillance and risk management activities including, but not limited to medical review of ICSRs, routine review of safety data, and pertinent scientific literature articles. Contribute to the review of assessments for safety signals or in response to Regulatory Authority requests.
  • Providing medical safety input into the design and conduct of pharmacoepidemiology and observational studies.
  • Plan and interpret safety data analyses, prepare and present safety data summaries to internal and external stakeholders.
  • Acquire and contribute knowledge of relevant drug class and/or competitor safety issues.
  • Lead the development of safety surveillance strategy, identify potential clinical safety issues, and recommend appropriate risk mitigation measures.
  • Establish and maintain collaborative working relationships with all key stakeholders (e.g., clinical study teams, safety CROs, business partners) which require expert contribution to the development of the product safety strategy.
  • Accountable for risk management activities including preparation and maintenance of relevant sections of clinical trial protocols, IBs (including the reference safety information section), ICFs, DSURs, RMPs, CCDS, and labelling, as required.
  • Contribute to regulatory authority submissions (Investigational New Drug applications, New Drug Applications, Marketing Authorization Applications, etc.).
  • Developing response strategies in collaboration with safety committee members, providing medical-scientific input to regulatory documents for safety-related requests from health authorities and other external parties.
  • Evaluates risk minimization strategies and takes accountability for the medical-scientific content in the Risk Management Plans, including risk minimization measures, risk minimization action plans and REMS programs, as relevant.
  • Accountable for the safety components of study reports (i.e., CSRs), aggregate reports (DSUR, PSUR/PBRER, PADER) and other regulatory documents.
  • Participate in internal and external Data Monitoring Committees through review of safety data, insights and leadership and development of DMC Charters.
  • Reviews publications, including abstracts, manuscripts, and speaker presentations.
  • Trains and mentors Safety Scientists.
  • Consistently comply with all governing laws, regulations, RevMed standard operating procedures (SOPs) and other guidelines.
Desired Qualifications
  • Demonstrated ability to lead and influence in a global matrix environment.
  • 2+ years of experience in Oncology clinical development
  • Proficiency in managing regulatory interactions, BLA/MAA experience.
  • Strong organizational and time management skills, with the ability to prioritize and manage multiple tasks effectively.
  • Excellent influence and collaboration/teamwork capabilities.
  • Strong interpersonal and communication (written and verbal) skills

Revolution Medicines focuses on developing treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines targets a niche market of RAS-driven cancers, working closely with healthcare providers and institutions to deliver their treatments. Their goal is to transform cancer care by providing effective, targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital, boosting financial stability.
  • $600M public stock offering shows strong investor confidence and funding for projects.
  • Recognition by the Lustgarten Foundation enhances their reputation in oncology.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M stock offering could dilute existing shareholder value, causing dissatisfaction.
  • Focus on RAS-addicted cancers limits market scope and risks competition.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural product analogues.
  • Their Tri Complex Inhibitor platform targets RAS proteins, a critical cancer growth driver.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

7%
PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders